PMDA drug package insert
ベクロメタゾン点鼻液50μg「CEO」
PMDA Prescription drug · セオリア ファーマ株式会社 · package insert Jul 31, 2024
Key facts
| Brand names | ベクロメタゾン点鼻液50μg「CEO」 |
|---|---|
| Nonproprietary names | ベクロメタゾンプロピオン酸エステル |
| Companies | 製造販売元／セオリア ファーマ株式会社, 販売／武田薬品工業株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 噴霧吸入式鼻過敏症治療剤 |
| Therapeutic category codes | 871329 |
| YJ codes | 1329702R3209 |
| Approval numbers | 30200AMX00045 |
| Package insert edition | 第2版 |
| Package insert date | Jul 31, 2024 |
| PMDA document key | 380999_1329702R3209_1 |
| PMDA company code | 380999 |
At a glance
- 1–9 Package insert revisions
- 1–9 Related PMDA documents
- None Safety communications
- No PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: